S. 1096 · 119th Congress (2025–2027)
Preserve Access to Affordable Generics and Biosimilars Act
This bill prohibits parties from entering into any agreement that resolves or settles a patent claim related to the sale of a drug or biological product and that has anticompetitive effects. Such an agreement is presumed to have anticompetitive effects if the filer of a generic drug or biosimilar application receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar.
An agreement is exempt if the only consideration granted to the generic manufacturer is (1) the right to market and secure final approval for its product prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on any claim that the generic drug or biosimilar infringes a U.S. patent. An agreement is also exempt if the agreement's pro-competitive benefits outweigh the anticompetitive effects.
The bill provides for enforcement by the Federal Trade Commission (FTC). Violators are subject to penalties including the forfeiture of the 180-day marketing exclusivity period for a generic drug.
Additionally, when a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing, or sale of a drug, the manufacturers must certify that the material they have given the FTC and the Department of Justice concerning the agreement contains the complete agreement and any related agreements, including descriptions of any oral agreements or representations.
Show official title
A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
Reported
This bill’s path
This is S. 1096’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
- Sponsor
- Sen. Amy Klobuchar (D-MN)
- Cosponsors
8 cosponsors
8 original · 0 later
3 R · 5 D
- Sen. Richard Blumenthal (D-CT)· Original · Mar 24, 2025
- Sen. Cory A. Booker (D-NJ)· Original · Mar 24, 2025
- Sen. Kevin Cramer (R-ND)· Original · Mar 24, 2025
- Sen. Richard J. Durbin (D-IL)· Original · Mar 24, 2025
- Sen. Joni Ernst (R-IA)· Original · Mar 24, 2025
- Sen. Chuck Grassley (R-IA)· Original · Mar 24, 2025
- Sen. Mark Kelly (D-AZ)· Original · Mar 24, 2025
- Sen. Peter Welch (D-VT)· Original · Mar 24, 2025
- Policy area
- Health
- Subjects
- Administrative law and regulatory procedures
- Civil actions and liability
- Competition and antitrust
- Contracts and agency
- Federal Trade Commission (FTC)
- Intellectual property
- Judicial review and appeals
- Licensing and registrations
3 more
- Manufacturing
- Marketing and advertising
- Prescription drugs
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
▸ 3 committee actions · Mar 24, 2025 – Apr 10, 2025
Referred to committee
Read twice and referred to the Committee on the Judiciary.
Sources
- Congress.gov action
- Senate
Ordered reported
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Sources
- Congress.gov action
- Senate
Reported by committee
Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
Sources
- Congress.gov action
- Senate
Committees
Apr 3, 2025 · Meeting
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
Titles (2)
Preserve Access to Affordable Generics and Biosimilars Act
Short title, Display title · Reported to Senate, Introduced in Senate
A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
Official title · Introduced in Senate